Mao B Inhibitors plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Mao B Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Monoamine oxidase type B (MAO-B) inhibitors are a class of drugs widely used in the treatment of [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- that work by blocking
the enzyme responsible for the breakdown of [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- in the brain. Three MAO-B inhibitors are currently approved for clinical use:
selegiline (first generation), rasagiline (second generation), and safinamide (third generation) [[1])]https://pmc.ncbi.nlm.nih.gov/articles/PMC7052841/).
Among all classes of
anti-parkinsonian drugs, MAO-B inhibitors have demonstrated the greatest neuroprotective potential in preclinical studies, through
mechanisms including reduction of [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--, inhibition of [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- metabolism, and stimulation of neurotrophic factor release
[[2]https://www.parkinsons.org.uk/information/drugs/mao-b.
[dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- released from nigrostriatal terminals in the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- is metabolized through two main pathways:
- MAO-B pathway: Dopamine → 3,4-dihydroxyphenylacetaldehyde (DOPAL) → 3,4-dihydroxyphenylacetic acid (DOPAC)
- COMT pathway: Dopamine → 3-methoxytyramine (3-MT)
MAO-B catalyzes the first step in the primary degradation pathway. This reaction generates [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- (hydrogen peroxide,
H₂O₂) as a byproduct, which contributes to [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- and nigrostriatal neurodegeneration [4].
MAO-B is located predominantly on the outer mitochondrial membrane of [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- and serotonergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in the
brain. Its expression increases with age and in neurodegenerative conditions, making it both a therapeutic target and a potential
contributor to disease progression [1]
¶ Landmark Clinical Trials
The Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial was the first large multicenter study examining early
selegiline treatment in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- [[1])]https://pmc.ncbi.nlm.nih.gov/articles/PMC7052841/):
- Design: 800 patients with early, untreated PD randomized to selegiline (10 mg/day), tocopherol (vitamin E, 2000 IU/day), both, or placebo
- Primary endpoint: Time to requiring [levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa--TEMP--/treatments)--FIX-- therapy
- Results: Selegiline delayed the need for levodopa by approximately 9 months. Tocopherol showed no benefit
- Controversy: The observed benefit was debated as being purely symptomatic rather than neuroprotective, as the drug washout period (2 months) was shorter than the time required for full recovery of MAO-B activity after irreversible inhibition
The Attenuation of Disease Progression with Azilect Given Once-daily (ADAGIO) trial tested whether rasagiline had disease-modifying effects [[5]]https://www.nature.com/articles/s41531-022-00339-2):
- Design: 549 mid-to-late PD patients on levodopa plus other PD medications, randomized to safinamide (50–100 mg/day) or placebo for 24 weeks
- Results: Safinamide significantly increased daily "on" time by 1.42 hours vs. 0.57 hours for placebo, decreased "off" time, and improved UPDRS motor scores
- Long-term extension (MOTION): Sustained benefits observed over 2 years
MAO-B inhibitors have consistently demonstrated the greatest neuroprotective potential among all classes of anti-parkinsonian drugs [[2])]https://journals.lww.com/nrronline/fulltext/2024/01000/type_b_monoamine_oxidase_inhibitors_in.3.aspx):
- Reduction of oxidative stress: By inhibiting MAO-B, these drugs decrease the production of H₂O₂ and other [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- generated during dopamine metabolism
- Anti-apoptotic effects: Propargylamine-containing compounds (selegiline, rasagiline) upregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and downregulate pro-apoptotic factors (Bad, Bax, [caspases)
- Neurotrophic factor induction: Stimulate production and release of [GDNF[/entities/[gdnf[/entities/[gdnf[/entities/[gdnf--TEMP--/entities)--FIX-- (glial cell line-derived neurotrophic factor) and [BDNF[/entities/[bdnf[/entities/[bdnf[/entities/[bdnf--TEMP--/entities)--FIX-- (brain-derived neurotrophic factor), which support dopaminergic neuron survival
- Anti-inflammatory effects: Reduce [microglial/striatum]
- Glutamate modulation (safinamide): Inhibits excessive glutamate release, counteracting [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX-- in the basal ganglia motor
circuit [[2])]https://journals.lww.com/nrronline/fulltext/2024/01000/type_b_monoamine_oxidase_inhibitors_in.3.aspx)
Recent systematic reviews have highlighted MAO-B inhibitor benefits beyond motor symptoms [6]:
- Quality of life: Rasagiline and safinamide significantly improved quality of life measures (PDQ-39) compared to placebo
- Depression: Safinamide demonstrated improvements in depression scores, potentially through its dual dopaminergic/glutamatergic mechanism
- Pain: Safinamide reduced musculoskeletal and neuropathic pain in PD patients
- Fatigue: Both rasagiline and safinamide showed benefits for fatigue
- Sleep: Mixed results; selegiline may worsen insomnia due to amphetamine metabolites, while rasagiline and safinamide have neutral to beneficial effects
- Cognition: Some evidence for cognitive benefit, particularly with rasagiline, possibly through noradrenergic and serotonergic effects [7]
¶ Safety and Drug Interactions
- Selegiline: Insomnia, nausea, orthostatic hypotension, confusion, hallucinations (especially in elderly)
- Rasagiline: Headache, arthralgia, dyspepsia, dizziness
- Safinamide: Dyskinesia (when added to levodopa), nausea, falls, insomnia
- Tyramine-containing foods: At therapeutic doses, MAO-B inhibitors have minimal risk of the "cheese effect" (hypertensive crisis), unlike non-selective MAO inhibitors. Risk increases only at supratherapeutic doses that inhibit MAO-A [1].
MAO-B inhibitors are being investigated for other neurodegenerative conditions [[2])]https://journals.lww.com/nrronline/fulltext/2024/01000/type_b_monoamine_oxidase_inhibitors_in.3.aspx):
- [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: MAO-B activity is elevated in [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- surrounding [amyloid plaques]; selegiline and rasagiline have shown modest cognitive benefits in AD trials. Novel MAO-B inhibitors that also target amyloid are in development
- [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--: Rasagiline demonstrated a potential disease-modifying effect in ALS clinical trials, possibly through anti-apoptotic mechanisms
- [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--: Preclinical evidence suggests neuroprotective effects in striatal [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
- Depression: Selegiline transdermal patch (Emsam) is FDA-approved for major depressive disorder
- Traumatic brain injury: Neuroprotective potential under investigation
- [Dopamine Agonists in Parkinson's Disease[/treatments/[dopamine-agonists[/treatments/[dopamine-agonists[/treatments/[dopamine-agonists--TEMP--/treatments)--FIX--
- [Levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa--TEMP--/treatments)--FIX--
The study of Mao B Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mao B Inhibitors plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
- [Finberg JPM, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol. 2016;7:340. [Different generations of type-B monoamine oxidase inhibitors in Parkinson's Disease: from bench to bedside. Curr Pharm Des. 2020;26(24):2879-2890. PMC))
- [Tan YY, Jenner P, Chen SD. Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regen Res. 2024;19(1):16-21. LWW)
- Parkinson's UK. MAO-B inhibitors (rasagiline, selegiline, safinamide]. Parkinson's UK Information. 2024. [Parkinson's UKhttps://www.parkinsons.org.uk/information/drugs/mao-b
- [Naoi M, Maruyama W, Shamoto-Nagai M. An overview of the role of monoamine oxidase-B in Parkinson's Disease: implications for neurodegeneration and therapy. Explor Neuroprot Ther. 2024;4:67-84. Exploration Publishing)
- [Szökő É, Tábi T, Riederer P, Vécsei L, Magyar K. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's Disease. J Neural Transm. 2022;129(5-6]:723-740. Springer)
- [Giossi R, Carrara F, Calogero AM, et al. Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's Disease: a systematic review. npj Parkinsons Dis. 2022;8:88. Nature)
- [Araújo B, Silva AR, Torres T, et al. Effects of MAO-B inhibitors on life quality of Parkinson's Disease patients: a systematic review and meta-analysis. Behav Brain Res. 2024;480:115377. ScienceDirect)
- [Zhang Y, et al. Safety comparisons among monoamine oxidase inhibitors against Parkinson's Disease using FDA adverse event reporting system. Sci Rep. 2023;13:17803. Nature)